<code id='ED2BB1A8C7'></code><style id='ED2BB1A8C7'></style>
    • <acronym id='ED2BB1A8C7'></acronym>
      <center id='ED2BB1A8C7'><center id='ED2BB1A8C7'><tfoot id='ED2BB1A8C7'></tfoot></center><abbr id='ED2BB1A8C7'><dir id='ED2BB1A8C7'><tfoot id='ED2BB1A8C7'></tfoot><noframes id='ED2BB1A8C7'>

    • <optgroup id='ED2BB1A8C7'><strike id='ED2BB1A8C7'><sup id='ED2BB1A8C7'></sup></strike><code id='ED2BB1A8C7'></code></optgroup>
        1. <b id='ED2BB1A8C7'><label id='ED2BB1A8C7'><select id='ED2BB1A8C7'><dt id='ED2BB1A8C7'><span id='ED2BB1A8C7'></span></dt></select></label></b><u id='ED2BB1A8C7'></u>
          <i id='ED2BB1A8C7'><strike id='ED2BB1A8C7'><tt id='ED2BB1A8C7'><pre id='ED2BB1A8C7'></pre></tt></strike></i>

          Home / fashion / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:6

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In